Male Breast Carcinoma Recruiting Phase 2 Trials for Lapatinib (DB01259)

IndicationStatusPhase
DBCOND0030384 (Male Breast Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01622868Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast CancerTreatment